Effect of pre‐treatment with nicotine patch on withdrawal symptoms and abstinence rates in smokers subsequently quitting with the nicotine patch: a randomized controlled trial
- 8 April 2004
- Vol. 99 (5) , 634-640
- https://doi.org/10.1111/j.1360-0443.2004.00711.x
Abstract
To determine whether 2-week pre-treatment with transdermal nicotine influences withdrawal symptoms or success rate of subsequent smoking cessation using nicotine patches. Randomized controlled trial. Smoking cessation clinic. Healthy smokers (n = 200, 45% female) were allocated randomly to either active nicotine-patch (AP, 15 mg daily, n = 100) or placebo-patch (PP, n = 100) pre-treatment. Baseline characteristics were well balanced except for daily cigarette consumption: mean (+/- SD) 23.1 (8) and 26.4 (11) for AP and PP groups, respectively (P = 0.021). At the screening visit (-2 weeks) subjects were counselled and started pre-treatment with daily patches (AP or PP). From the quit date (week 0) onwards all subjects received active nicotine patches for 12 weeks (15 mg daily for 8 weeks, 10 and 5 mg daily for 2 weeks each) and counselling. Follow-up visits included measurement of exhaled carbon monoxide at the quit date, 2, 6, 10 and 26 weeks. Subjects documented daily cigarette consumption and severity of withdrawal symptoms (Wisconsin scale) from -2 weeks to week 2. Outcome measures were withdrawal symptoms composite score and abstinence rates. There was no significant difference in withdrawal symptoms, but more subjects in the AP group were smoke-free during the 6-month study period. Overall sustained abstinence was documented in 17% of subjects at 6 months; 22% and 12% for AP and PP, respectively (P = 0.03). Retrospective subgroup analysis showed for subjects smoking >16 cigarettes/day sustained cessation rates were 22% and 9% for AP and PP, respectively (P = 0.01). No difference in adverse event rates was observed. Nicotine patch pre-treatment before cessation did not reduce early withdrawal symptoms but increased sustained abstinence rates at 6 months. The nicotine pre-treatment was equally effective in light and heavy smokers.Keywords
This publication has 13 references indexed in Scilit:
- Nicotine concentrations with concurrent use of cigarettes and nicotine replacement: A reviewNicotine & Tobacco Research, 2002
- Aiding reduction of smoking with nicotine replacement medications: hope for the recalcitrant smoker?Tobacco Control, 1997
- Importance of baseline cotinine plasma values in smoking cessation: results from a double-blind study with nicotine patchEuropean Respiratory Journal, 1996
- Nicotine Gum, 2 and 4 mg, for Nicotine DependenceChest, 1995
- Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practiceAddiction, 1995
- Nicotine Patch Therapy for Smoking Cessation Combined With Physician Advice and Nurse Follow-upPublished by American Medical Association (AMA) ,1994
- Predicting Smoking CessationJAMA, 1994
- Two Studies of the Clinical Effectiveness of the Nicotine Patch With Different Counseling TreatmentsChest, 1994
- Effect of transdermal nicotine patches on cigarette smoking: a double blind crossover studyPsychopharmacology, 1992
- Signs and Symptoms of Tobacco WithdrawalArchives of General Psychiatry, 1986